BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted, off-the-shelf cellular immunotherapies for cancer, including its lead Bria-IMT candidate currently undergoing a pivotal Phase 3 clinical trial for metastatic breast cancer. Pulse 2.0 interviewed BriaCell Therapeutics CEO Dr. William Williams to learn more about his background, the company’s origins, its cancer immunotherapy platform, clinical research, competitive advantages, and plans to expand its treatments across multiple solid tumor types.
Dr. William Williams’ Background
When asked about his background, Williams shared:
I’ve spent over 35 years in medicine and biotech, starting with my training at MIT and Tufts Medical School, which led into specialized clinical training where I earned board certifications in internal medicine, immunology, and rheumatology.
While serving on the faculty at the University of Pennsylvania School of Medicine, I headed research in receptor biology, worked on bioactive peptide design, and collaborated on early DNA vaccines, introducing them into the clinic.
I eventually left academia for industry to gain practical knowledge in drug development, holding leadership roles at SmithKline Beecham/GlaxoSmithKline and later Incyte. That gave me hands-on, end-to-end expertise in taking therapies all the way from first-in-human studies through NDAs and post-approval marketing across oncology, autoimmunity, and metabolic diseases.
When I was introduced to BriaCell, I saw a compelling scientific concept that needed experienced drug development leadership to get off the ground, and that’s what brought me into my role as CEO.
BriaCell’s Mission And Approach To Cancer Treatment
When asked about BriaCell’s mission and the clinical needs the company seeks to address, Williams explained:
At BriaCell, our entire focus is on giving late-stage cancer patients better options and longer lives.
When patients reach advanced stages of cancer and exhaust standard treatments like chemotherapies, ADCs, or checkpoint inhibitors, clinicians are often left with almost no effective choices that do not bring devastating toxicities.
We are changing that by developing targeted whole-cell immunotherapies that awaken and hyper-activate the body’s own immune system to destroy resistant tumors.
Our mission is to bridge this gap with off-the-shelf, personalized therapies, starting with our lead candidate Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.
The goal is to deliver real survival benefits without sacrificing patient quality of life.
Beyond breast cancer, we are extending this personalized off-the-shelf approach across our broader pipeline, including Bria-PROS+ for prostate cancer, Bria-LUNG+ for lung cancer, and Bria-MEL+ for melanoma.
How The Idea For BriaCell Came Together
When asked about the company’s origins and how he became involved, Williams explained:
The original concept goes back to our scientific founder, Dr. Charles Wiseman, who was developing cancer cell lines at a hospital in Los Angeles to immunize patients facing similar cancers.
Working with Dr. Alex Kharazi, he developed Bria-IMT and saw a remarkable clinical response in one of the very first patients treated back in 2005.
When his funding dried up, he actually had to freeze the cell lines in liquid nitrogen and keep them in his garage. They stayed there until 2014, when he connected with a team that put the therapy into GMP production.
I heard about the company in 2016 through a board member. Looking at the early clinical data, I noticed that patient responses directly correlated with HLA tissue matching, which made total sense immunologically.
The company needed drug development experience to move forward, so I stepped in.
It has been quite a journey for us as a company, nearly running out of money during COVID before listing on NASDAQ in 2021, but we persevered to build the late-stage clinical pipeline we have today.
Favorite Memory Working At BriaCell
When asked about his favorite memory working at the company, Williams described clinical responses observed among patients participating in BriaCell’s research:
Without a doubt, it is seeing dramatic clinical responses in patients who had run out of options.
Early on in our clinical trials around 2017, we treated a woman who had 20 lung metastases from her breast cancer. After receiving our cellular immunotherapy, those 20 lung tumors either completely disappeared or shrank down into tiny scars.
Subsequently we have had patients with breast cancer metastases behind the eye, causing proptosis (eye bulging), and brain metastases resolve.
Moments like that, where you see a patient extend their life with minimal side effects after being told there was nothing left to try, make all the hard work and long hours completely worth it.
How Bria-IMT Immunotherapy Works
When asked how BriaCell’s Bria-IMT immunotherapy works and about its potential to transform cancer treatment, Williams explained:
Bria-IMT is a whole-cell targeted immunotherapy derived from a human breast cancer cell line genetically engineered to release GM-CSF and irradiated (so the cells can’t grow) before use.
It is used in combination with a couple of other drugs at low doses to help boost the immune response.
We administer it as a simple set of intradermal inoculations directly into the skin right in a physician’s office.
Once injected, the cells act similarly to antigen-presenting cells that release GM-CSF, stimulating local immune cells to go after matching tumor antigens throughout the body.
What makes this technology special is that it drives a dual activation: it stimulates adaptive immune cells (CD4+ and CD8+ T cells) while simultaneously activating the innate immune system, including Natural Killer cells.
That second part is vital because tumors often mutate to hide their HLA markers and escape T cells, but Natural Killer cells step in to eliminate those mutated cells.
In our Phase 2 trials, our therapy approximately doubled overall survival in advanced patients compared to historical controls, and it has been well tolerated with mostly local skin irritation at the injection site.
What Differentiates BriaCell From Its Competition
When asked what distinguishes BriaCell’s approach from other cellular immunotherapies, Williams explained:
Most cellular therapy approaches, like CAR-T or dendritic cell vaccines, rely on autologous manufacturing.
That means harvesting a patient’s own cells, shipping them to a central facility, custom re-engineering them over several weeks, and shipping them back.
It is wildly expensive, creates massive logistical backlogs, and makes sick patients wait weeks for treatment.
BriaCell completely avoids those bottlenecks by using pre-manufactured, frozen cell banks.
Our therapies are kept in a standard liquid nitrogen freezer, shipped to the clinic, thawed in minutes, and injected on the spot.
Furthermore, our next-generation Bria-OTS platform uses a quick saliva test to match over 99% of patients based on tissue type, giving us the precision of personalized medicine with the low cost and ease of an off-the-shelf drug.
Future Company Goals And Clinical Development Milestones
When asked about BriaCell’s upcoming goals, Williams outlined the company’s clinical development and commercialization priorities:
Our most significant near-term milestone is advancing our ongoing pivotal Phase 3 clinical trial in metastatic breast cancer toward its first interim efficacy analysis, anticipated later this year.
From there, we will be looking ahead to BLA submissions and commercialization.
We are also actively broadening our pipeline into other high-unmet-need indications.
Having secured FDA clearance for our INDs, we are initiating patient dosing for our off-the-shelf platform in both prostate cancer (Bria-PROS+) and breast cancer (Bria-BRES+), while advancing our preclinical genetic engineering work for lung cancer and melanoma.
Looking out over the next three years, our goal is to get our lead candidate onto the market to generate revenue, partner with larger pharma companies, and validate our pipeline across multiple solid tumor types.
The Impact Of Moderna And Merck’s Melanoma Vaccine On Cancer Immunotherapy
When asked about the impact of Moderna and Merck’s melanoma vaccine development on the broader immunotherapy industry, Williams explained:
The progress Merck and Moderna have made with their mRNA-based melanoma vaccine has generated significant attention and represents a deeply encouraging development that validates the broader potential of therapeutic cancer vaccines targeting the adaptive immune system.
I am encouraged by their results because proving that personalized immunotherapies can extend patient survival is a massive win for the entire oncology field.
At the same time, their success highlights a clear difference in strategic approach.
Their process requires a surgical tumor biopsy, complex genetic sequencing, and custom mRNA manufacturing built from scratch for every individual patient, which creates a multi-week waiting period and carries exorbitant costs.
BriaCell’s whole-cell platform, like our Bria-MEL+ candidate, presents a complete array of cancer antigens alongside built-in immune activators that stimulate both the adaptive and innate immune systems, providing a robust immune response without custom manufacturing delays.
While their breakthrough proves the clinical concept, it underscores why our off-the-shelf model is so vital, as we can deliver the precision of personalized immunotherapy immediately in a doctor’s office when time is of the essence for late-stage patients.
The Future Of Personalized Cancer Immunotherapy
When asked whether there were any additional topics he wanted to discuss, Williams emphasized the potential of emerging cellular immunotherapies to change the treatment landscape for patients with advanced cancers:
Looking at the broader trajectory of oncology, we are standing at a major turning point in how we approach targeted cancer care.
For years, the industry relied heavily on broad systemic treatments, but as tumors evolve resistance to checkpoints and targeted agents, the future clearly belongs to multi-pronged cellular immunotherapies that can outsmart cancer’s ability to mutate.
The real frontier now is taking these complex biological approaches and making them scalable, practical, and accessible for everyday clinical practice.
What excites me most about where the industry is headed is our growing ability to combine off-the-shelf speed with true genetic personalization.
As platforms like ours continue to mature, we are moving toward a reality where advanced cancer patients can receive immediate, precisely targeted immune activation right in their doctor’s office, fundamentally shifting late-stage cancer from a terminal diagnosis into a manageable condition.
